Upsher-Smith Launches Clonidine Hydrochloride Extended-Release Tablets

Jan. 30. 2020

Maple Grove, MN – January 28, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of Clonidine Hydrochloride Extended-Release Tablets in 0.1mg strength (the branded product: Kapvay®*). The product was approved by the U.S. Food and Drug Administration (FDA).

Clonidine Hydrochloride Extended-Release Tablets 0.1mg is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

The clonidine hydrochloride extended-release tablet market had U.S. sales of approximately $30 million for the 12 months ending November 2019 according to IQVIA.

*Kapvay is a registered trademark of Concordia Pharmaceuticals Inc.

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit